Core Insights - Milestone Pharmaceuticals announced a moderated poster presentation on the minimal blood pressure effects of intranasal etripamil for treating paroxysmal supraventricular tachycardia (PSVT) at the 2026 American College of Cardiology Annual Scientific Session [1][4] - Etripamil, a novel calcium channel blocker, was FDA-approved in December 2025 as the first self-administered treatment for symptomatic PSVT in adults [6][9] Data Highlights - The Phase 3 trials showed that etripamil had minimal impact on blood pressure, with a mean systolic BP change of 1.8 mmHg (SD 11.2) for a single 70 mg dose and 0.0 mmHg (SD 12.0) for repeat doses [6] - Among 1,610 patients, treatment-emergent adverse events (TEAEs) of hypotension were 0.4% (N=7) and syncope were 0.2% (N=4), with all TEAEs resolving without medical intervention [6] Presentation Details - The moderated poster presentation will be held on March 29, 2026, at 10:06 AM CT, presented by Dr. Narendra Singh [4] - An Expert Theater session will also explore CARDAMYST as an emerging therapy for symptomatic PSVT episodes [4] About CARDAMYST - CARDAMYST (etripamil) is designed for self-administration, allowing patients to manage acute symptomatic episodes of PSVT without immediate medical oversight [9] - The product is currently in Phase 2 development for pediatric patients and Phase 3 for atrial fibrillation with rapid ventricular rate [9]

Company Overview - Milestone Pharmaceuticals Inc. (MIST) has received approval for its first commercial product, CARDAMYST nasal spray, aimed at converting acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults [1][3]. Product Details - CARDAMYST nasal spray is a novel and rapid-acting calcium channel blocker designed for self-administration during unpredictable episodes of PSVT, marking the first FDA-approved treatment for this condition in over 30 years [3]. - The product is expected to be available in retail pharmacies by the first quarter of 2026 [3]. Market Context - PSVT affects more than two million Americans, with episodes characterized by rapid heart rates ranging from 160 to over 250 beats per minute, often occurring suddenly [2]. - Symptoms associated with PSVT include palpitations, sweating, chest pressure or pain, shortness of breath, sudden fatigue, fainting, and anxiety [2]. Stock Performance - On January 29, 2025, MIST was trading around $1.98, and it reached a 52-week high of $3.06 during intraday trading on December 12, 2025, before closing at $2.41, reflecting an 18.31% decline [4].